# PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

> **NCT06086457** · PHASE3 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 436 (estimated)

## Conditions studied

- Esophageal Neoplasms

## Interventions

- **RADIATION:** Radiation
- **DRUG:** TP or PF regimen depended on investigator's choice.
- **BIOLOGICAL:** PD-1 inhibitor

## Key facts

- **NCT ID:** NCT06086457
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-04
- **Primary completion:** 2026-06-28
- **Final completion:** 2029-08-28
- **Target enrollment:** 436 (ESTIMATED)
- **Last updated:** 2024-07-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06086457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06086457, "PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06086457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*